These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 23426454

  • 1. A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial.
    Stollman N, Magowan S, Shanahan F, Quigley EM, DIVA Investigator Group.
    J Clin Gastroenterol; 2013 Aug; 47(7):621-9. PubMed ID: 23426454
    [Abstract] [Full Text] [Related]

  • 2. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials.
    Raskin JB, Kamm MA, Jamal MM, Márquez J, Melzer E, Schoen RE, Szalóki T, Barrett K, Streck P.
    Gastroenterology; 2014 Oct; 147(4):793-802. PubMed ID: 25038431
    [Abstract] [Full Text] [Related]

  • 3. Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot study.
    Tuteja AK, Fang JC, Al-Suqi M, Stoddard GJ, Hale DC.
    Scand J Gastroenterol; 2012 Oct; 47(10):1159-64. PubMed ID: 22783919
    [Abstract] [Full Text] [Related]

  • 4. Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights.
    Strate LL, Modi R, Cohen E, Spiegel BM.
    Am J Gastroenterol; 2012 Oct; 107(10):1486-93. PubMed ID: 22777341
    [Abstract] [Full Text] [Related]

  • 5. Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon.
    Tursi A, Brandimarte G, Giorgetti GM, Elisei W, Aiello F.
    Int J Colorectal Dis; 2007 Sep; 22(9):1103-8. PubMed ID: 17390144
    [Abstract] [Full Text] [Related]

  • 6. Effect of oral mesalamine on inflammatory response in acute uncomplicated diverticulitis.
    Nespoli L, Lo Bianco G, Uggeri F, Romano F, Nespoli A, Bernasconi DP, Gianotti L.
    World J Gastroenterol; 2015 Jul 21; 21(27):8366-72. PubMed ID: 26217088
    [Abstract] [Full Text] [Related]

  • 7. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG.
    J Clin Gastroenterol; 2012 Mar 21; 46(3):220-7. PubMed ID: 22157240
    [Abstract] [Full Text] [Related]

  • 8. Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon--a placebo-controlled study.
    Kruis W, Meier E, Schumacher M, Mickisch O, Greinwald R, Mueller R, German SAG-20 Study Group.
    Aliment Pharmacol Ther; 2013 Apr 21; 37(7):680-90. PubMed ID: 23414061
    [Abstract] [Full Text] [Related]

  • 9. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
    Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y.
    Clin Gastroenterol Hepatol; 2006 Dec 21; 4(12):1502-6. PubMed ID: 17101300
    [Abstract] [Full Text] [Related]

  • 10. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
    Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P.
    Gastroenterol Clin Biol; 2008 Feb 21; 32(2):147-52. PubMed ID: 18387426
    [Abstract] [Full Text] [Related]

  • 11. Diclofenac potassium liquid-filled soft gelatin capsules in the management of patients with postbunionectomy pain: a Phase III, multicenter, randomized, double-blind, placebo-controlled study conducted over 5 days.
    Riff DS, Duckor S, Gottlieb I, Diamond E, Soulier S, Raymond G, Boesing SE.
    Clin Ther; 2009 Oct 21; 31(10):2072-85. PubMed ID: 19922878
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS, Riff DS, Pruitt R, Wruble L, Koval G, Sales D, Bell JK, Johnson LK.
    Am J Gastroenterol; 2002 Jun 21; 97(6):1398-407. PubMed ID: 12094857
    [Abstract] [Full Text] [Related]

  • 13. Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers.
    Joeres-Nguyen-Xuan TH, Boehm SK, Joeres L, Schulze J, Kruis W.
    Inflamm Bowel Dis; 2010 Feb 21; 16(2):256-62. PubMed ID: 19637333
    [Abstract] [Full Text] [Related]

  • 14. [Probiotics for prevention of ulcerative colitis recurrence: alternative medicine added to standard treatment?].
    Folwaczny C.
    Z Gastroenterol; 2000 Jun 21; 38(6):547-50. PubMed ID: 10923365
    [No Abstract] [Full Text] [Related]

  • 15. [Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine].
    Adam B, Liebregts T, Holtmann G.
    Z Gastroenterol; 2006 Mar 21; 44(3):267-9. PubMed ID: 16514573
    [No Abstract] [Full Text] [Related]

  • 16. Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating.
    Ringel-Kulka T, McRorie J, Ringel Y.
    Am J Gastroenterol; 2017 Jan 21; 112(1):145-151. PubMed ID: 27845337
    [Abstract] [Full Text] [Related]

  • 17. A multicenter, randomized, double-blind, placebo-controlled trial of intravenous ibuprofen 400 and 800 mg every 6 hours in the management of postoperative pain.
    Southworth S, Peters J, Rock A, Pavliv L.
    Clin Ther; 2009 Sep 21; 31(9):1922-35. PubMed ID: 19843482
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the analgesic effect of ibuprofen with mesalamine after discectomy surgery in patients with lumbar disc herniation: a double-blind randomized controlled trial.
    Toroudi HP, Borghei Razavi M, Borghei Razavi H, Tabatabayi RM, Tabar YT, Yahyavi ST, Montazer M.
    Neurol India; 2009 Sep 21; 57(3):305-9. PubMed ID: 19587472
    [Abstract] [Full Text] [Related]

  • 19. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F.
    Am J Gastroenterol; 2005 Nov 21; 100(11):2478-85. PubMed ID: 16279903
    [Abstract] [Full Text] [Related]

  • 20. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E.
    N Engl J Med; 1998 Aug 06; 339(6):370-4. PubMed ID: 9691103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.